SCHEMBL2486477

SCHEMBL2486477

COc1c(CCc2ccc(NS(C)(=O)=O)cc2)cc(-c2ncc[nH]c2=O)c(F)c1C(C)(C)C

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.55
DRD3 P35462 2/20 0.37
KCNH2 Q12809 2/20 0.33
BRD4 O60885 2/20 0.33
EP300 Q09472 1/20 0.33
CACNA1F O60840 1/20 0.33
CHRM2 P08172 1/20 0.33
ACHE P22303 1/20 0.33
AGTR1 P30556 1/20 0.33
CACNA1D Q01668 1/20 0.33
CACNA1S Q13698 1/20 0.33
CACNA1C Q13936 1/20 0.33
CYP17A1 P05093 1/20 0.32
IKBKB O14920 1/20 0.32
CHUK O15111 1/20 0.32
KIT P10721 1/20 0.31
CCNT1 O60563 1/20 0.31
CDK9 P50750 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6832548 0.86 CYP3A4 (0.38) CYP3A4
SCHEMBL1542343 0.85 CYP3A4 (0.70) CYP3A4DRD3BRD4EP300
SCHEMBL2487216 0.82 CYP3A4 (0.72) CYP3A4DRD3KCNH2BRD4EP300
SCHEMBL2746103 0.77 CYP3A4 (0.49) CYP3A4
SCHEMBL1542581 0.71 CYP3A4 (1.00) CYP3A4DRD3BRD4EP300
SCHEMBL1542399 0.70 CYP3A4 (0.75) CYP3A4DRD3KCNH2
SCHEMBL2491324 0.68 CYP3A4 (0.72) CYP3A4BRD4EP300IKBKBCHUK
SCHEMBL2487340 0.68 CYP3A4 (0.53) CYP3A4
SCHEMBL2491321 0.68 CYP3A4 (0.72) CYP3A4BRD4EP300IKBKBCHUK
SCHEMBL1542380 0.67 CYP3A4 (0.76) CYP3A4DRD3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US claimed
US-8178547-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-05-15 US disclosed
US-8178547-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-05-15 US disclosed
EP-2379534-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-10-26 EP disclosed
WO-2010072598-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 WO disclosed
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US disclosed
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS RFC1, RRP1B, RRBP1 CYP3A4 978/4885DRD3 1345/4885KCNH2 3568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.